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Abstract 
Objective: In 2013, the USPSTF issued a Grade B recommendation that long-term current and 
former smokers receive lung cancer screening. Shared decision-making is important for 
individuals considering screening, and patient-provider discussions an essential component of 
the process. We examined prevalence and predictors of lung cancer screening discussions pre- 
and post-USPSTF guidelines. 
Methods: Data were obtained from two cycles of the Health Information National Trends Survey 
(2012; 2014). The analyzed sample comprised screening-eligible current and former smokers 
with no personal history of lung cancer (n=746 in 2012; n=795 in 2014). Descriptive and multiple 
logistic regression analyses were conducted; patient-reported discussion about lung cancer 
screening with provider was the outcome of interest. 
Results: Contrary to expectations, patient-provider discussions about lung cancer screening 
were more prevalent pre-guideline, but overall patient-provider discussions were low in both 
years (17% in 2012; 10% in 2014). Current smokers were more likely to have had a discussion 
than former smokers. Significant predictors of patient-provider discussions included family 
history of cancer and having healthcare coverage. 
Conclusions: The prevalence of patient-provider discussions about lung cancer screening is 
suboptimal. 
Practice Implications: There is a critical need for patient and provider education about shared 




Lung cancer is the leading cause of cancer-related mortality for both genders in the 
United States accounting for an estimated 158,080 deaths in 2016 [1]. Most lung cancer 
patients are diagnosed with advanced disease, leading to low survival rates. Individuals with 
Stage IV lung cancer have a five-year relative survival rate of 1% [1]. Tobacco smoking is the 
number one risk factor for lung cancer and has been linked to 90% of all lung cancer cases [1]. 
Therefore, long-term smokers are at greatest risk for the development of lung cancer [2].  
In response to empirical findings from the National Lung Screening Trial, the United 
States Preventive Services Task Force (USPSTF) issued guidelines recommending annual low-
dose computed tomography (LDCT) for long-term smokers [3]. Specifically, current or former 
smokers aged 55 to 80 years who have quit within the past 15 years and have a 30-pack year 
or more tobacco smoking history are eligible for screening. Lung cancer screening with LDCT in 
long-term smokers has been shown to decrease relative lung cancer-related mortality by 20% 
via earlier identification and treatment [4]. The USPSTF’s Grade B recommendation reflects the 
conclusion that available evidence was sufficient, with high certainty, that annual LDCT will yield 
moderate to substantial benefits for this high-risk group. Further, the Centers for Medicare and 
Medicaid Services (CMS) approved coverage of LDCT for its high-risk beneficiaries in February 
2015 [5].  
As part of the recommendation and approval by CMS, documentation of a shared 
decision-making visit is required for reimbursement of lung cancer screening. CMS defines the 
shared decision-making visit as an encounter between a healthcare provider (physician, nurse 
practitioner, clinical nurse specialist, or physician assistant) and a screening-eligible patient that 
discusses the benefits and harms of screening, potential for follow-up diagnostic testing, over-
diagnosis, false positive rate, and total radiation exposure prior to the patient’s decision to 
screen [5]. In addition, the USPSTF recommends shared decision-making be incorporated into 
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lung cancer screening programs as they are implemented [3]. Shared decision-making is a 
process in which the patient is an active partner with the healthcare provider to clarify 
acceptable medical options and decide on a preferred course regardless of the patient’s cancer 
screening decision. 
As lung cancer screening becomes more widely promoted and available nationally, 
patients will likely be seeking information about lung cancer screening from a variety of sources 
including their healthcare provider. Consequently, providers are expected to be fielding more 
questions from patients about lung cancer screening. As the first cancer screening modality to 
specifically require documentation of a shared decision-making visit for reimbursement, the 
patient-provider discussion is essential.  It is critical to understand the trends of this encounter in 
lung cancer screening and the factors that influence and inform such discussions. However, no 
prior studies have examined the extent to which current and former smokers engage in 
discussions about lung cancer screening with their healthcare providers.  Healthcare provider 
recommendations are strong predictors of screening for other cancers [6-8] and are likely to be 
influential in the decision to participate, or not, in lung cancer screening. With the issuance of a 
Grade B recommendation from the USPSTF, it becomes valuable to document both baseline 
and trends in patient-provider discussions. Because patient-provider discussions are an 
important component of the shared decision-making process, understanding the prevalence of 
these discussions pre- and post-issuance of lung cancer screening guidelines has the potential 
to identify communication inequities. Further, the findings may guide future research focused on 
areas for promoting discussions between providers and their patients who are current and 
former smokers. 
1.1 Purpose 
 In this paper, we examine the prevalence of discussions about lung cancer screening in 
2012 (prior to the USPSTF lung cancer screening recommendation) compared with 2014 (post-
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recommendation) among current and former smokers aged 55 to 80 years using a U.S. 
nationally representative sample. We further identify the predictors of having a discussion with a 
healthcare provider about lung cancer screening pre- and post-guideline issuance among 
current and former smokers. 
2. Methods 
2.1 Data Source 
We obtained data from two recent rounds of the Health Information National Trends 
Survey (HINTS 4 Cycle 2 conducted between October 2012 and January 2013, and Cycle 4 
conducted between August and November 2014). These two survey cycles included a relevant 
question on patient-provider discussions about lung cancer screening for this study.  
2.2 Sample and Data Collection 
HINTS is a nationally representative cross-sectional survey, administered by the 
National Cancer Institute that collects data about the use of cancer-related information by U.S. 
adults aged 18 years and older. The study design and sampling framework have been 
described elsewhere [9]. Briefly, HINTS has a two-stage sampling design. The first stage uses a 
stratified sample of addresses selected from a file of U.S. residential addresses for inclusion. 
The second stage involves the selection of one adult within each sampled household using the 
Next Birthday Method. HINTS 4 Cycles 2 and 4 used a mailed paper and pencil questionnaire 
(available in both English and Spanish) for data collection. The overall response rate (RR2 
formula of the American Association for Public Opinion Research) for HINTS 4 Cycle 2 was 
40%, resulting in N = 3,630 completed questionnaires. The overall response rate for HINTS 4 
Cycle 4 was 34%, resulting in N = 3,677 completed questionnaires. In this study, we restricted 
the analyses to 746 respondents in Cycle 2 and 795 respondents in Cycle 4 who were either 
current or former smokers, aged 55 to 80 years, and who had no personal history of lung cancer 
(Figure 1). These criteria were adapted from screening eligibility criteria for lung cancer 
screening from the USPSTF guidelines and have been utilized in recent studies [10,11]. The 
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HINTS survey did not assess cigarette pack-year history and thus it was not among the 
inclusion criteria in our study.    
2.3 Measures 
The primary outcome variable is the dichotomous response to the question, “At any time 
in the past year, have you talked with your doctor or other health professional about having a 
test to check for lung cancer?” with response options of yes, no, and don’t know. The predictor 
variables included survey year (2012 and 2014), age (in years), sex, race/ethnicity (white, black, 
Hispanic, or other), education (less than high school to college graduate or higher), household 
annual income (less than $20,000 to $75,000 or higher), self-reported general health status 
(excellent to poor), smoking status (current or former smoker), personal history of cancer 
(excluding lung), family history of cancer, and healthcare coverage (e.g., health insurance, 
prepaid plans or HMO, or government plans such as Medicare). Missing, multiple responses, 
“inapplicable”, and “don’t know” answers were recoded as missing for analytic purposes. 
2.4 Data Analyses 
 Analyses were conducted using Stata version 13 using descriptive statistics and multiple 
logistic regression. We calculated the weighted prevalence of self-reported discussions with a 
doctor or healthcare professional about lung cancer screening and distributions of demographic 
and other variables in 2012 and 2014. We merged the two cycles of HINTS 4 data for the 
logistic regression following procedures described in the HINTS documentation for examining 
changes across years [12]. Analyses were performed using the jackknifed replication weights 
provided in the datasets. These weights account for sampling design, oversampling, and non-
response patterns in the data. Missing values on the outcome variable (n=62 in 2012; n=34 in 
2014) were omitted from the logistic regression model. Missing values in one or more predictor 
variables accounted for 16% of the analyzed sample. To reduce potential bias due to excluding 
these participants, missing values of each predictor variable were treated as a separate 
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category in the logistic regression model as described in previous research using the HINTS 
survey data [13].  
3. Results 
3.1 Prevalence of Patient-Provider Discussions and Sociodemographic Comparisons between 
Respondents in 2012 and 2014 
Table 1 summarizes the prevalence of patient-provider discussions about lung cancer 
screening in the past year and the characteristics of the analyzed samples in 2012 (Cycle 2) 
and 2014 (Cycle 4). Overall, a modest proportion of respondents had a discussion with their 
healthcare provider about lung cancer screening before (17% in 2012) and after (10% in 2014) 
the screening guidelines were issued. Mean age of the analyzed sample in both cycles was 
approximately 65 years. In addition, in both cycles, about half were female, predominantly white, 
had some college education or higher, reported household incomes below $75,000, self-
reported good to excellent health, had healthcare coverage, and were former smokers. Most did 
not have a personal history of cancer, although the majority reported having a family member 
who had a cancer diagnosis. There were no significant sociodemographic trend differences in 
2014 compared to those in 2012 in age, gender, race/ethnicity, education, income level, 
smoking status, personal history of cancer, or family history of cancer. When examining 
prevalence of discussions occurring by racial/ethnic group, similar prevalence was noted across 
all groups in both years.  
3.2 Predictors of Patient-Provider Discussions Pre- and Post-Lung Cancer Screening 
Guidelines 
 Multiple logistic regression analysis was performed to identify predictors of patient-
provider discussions about lung cancer screening (see Table 2). Respondents from the Cycle 4 
(2014) survey had about 53% lower odds of having a discussion about lung cancer screening 
with their healthcare provider than respondents from the Cycle 2 (2012) survey (odds ratio [OR], 
0.47; 95% confidence interval [CI], 0.31-0.72). In addition, current smokers had higher odds of 
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having such discussions than former smokers (OR, 2.25; CI, 1.34-3.79), and those who had a 
family history of cancer (OR, 2.53; CI, 1.43-4.48) and who had healthcare coverage (OR, 2.90; 
CI, 1.10-7.69) also had higher odds of reporting having a discussion with their healthcare 
provider about screening.  
4. Discussion and Conclusion 
4.1 Discussion 
 As clinical encounters evolve to incorporate shared decision-making in lung cancer 
screening decisions, increased focus on the patient-provider discussion is important. Shared 
decision-making is a moral obligation clinically, and the reimbursement requirement in lung 
cancer screening offers an incentive for shared decision-making to occur in the busy clinical 
encounter. The current landscape offers the opportunity to examine a key component of the 
shared decision-making process, the patient-provider discussion, and can be used to compare 
trends as the science advances in shared decision-making in cancer screening overall. 
 This study reveals patient-provider discussions occurred in less than 20% of screening-
eligible current and former smokers. Patient-provider discussions and subsequent healthcare 
provider recommendations are associated with increased cancer screening behavior in other 
types of cancer such as breast and colorectal with patient-provider discussions occurring in 
approximately 50 to 80% of screening eligible patients [15-17]. However, unlike many cancers, 
there is a higher level of stigma associated with lung cancer [18,19], which may be contributing 
to the overall low prevalence of patient-provider discussions in lung cancer screening. Smokers 
are a unique population different from those targeted for other types of cancer screening. 
Smokers experience stigma, battle an addiction to nicotine, and perceive blame from others 
related to the perceived self-infliction of tobacco-related diseases secondary to lifestyle choices 
[18,19]. Therefore, perceived stigma seems relevant in lung cancer screening.  
Patient-provider discussions of 17% and 10% respectively in 2012 and 2014 support a 
critical need for efforts targeting both patient and provider education. From the patient 
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perspective, educational efforts that support increasing awareness of lung cancer risk as well as 
the availability of lung cancer screening are essential. Equally, provider education about the 
importance of the shared decision-making process in lung cancer screening is crucial in order to 
enhance patient-provider discussions in this area. Further, given the unique relevance of stigma 
in lung cancer and its potential influence in screening, it is equally important that future 
educational efforts address the perception of stigma from the patient perspective as well as 
implicit and explicit stigma from the provider perspective in order to create an environment more 
conducive to effective discussions about screening and prevention. 
 We expected the prevalence of patient-provider discussions to increase after lung 
cancer screening guidelines were issued, particularly given the specific language related to 
shared decision-making in the USPSTF recommendation. However, the findings suggest the 
reverse occurred—there were fewer discussions in 2014 compared to 2012. It is plausible that 
the findings are affected by increased discussions in 2012 following heightened media coverage 
of the landmark findings of decreased mortality rates with annual LDCT in the National Lung 
Screening Trial in 2011 [20,21]. These findings were released in late 2010 resulting in increased 
media coverage via print and electronic communication about the benefits of lung cancer 
screening, which may have contributed to more patients raising the topic with their healthcare 
providers. 
 Current smokers were more likely than former smokers to have this discussion. Patient-
provider discussions about lung cancer screening with current smokers offers a timely 
opportunity for both shared decision-making about cancer screening as well as the opportunity 
of a potentially teachable moment for smoking cessation. These encounters offer an 
environment encapsulated by the clinical encounter to first assess the stage of readiness of the 
current smoker and subsequent intervention to promote smoking cessation. This intervention 
can extend to future clinical encounters such as follow-up for screening results offering 
additional opportunities to intervene and promote smoking cessation. In addition, our study 
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found that insured patients were more likely to have these discussions with their healthcare 
provider compared with uninsured patients. This underscores the need for lung cancer 
screening programs for the uninsured and underserved similar to the National Breast and 
Cervical Cancer Early Detection Screening Program. 
While it is important for these discussions to occur between current smokers and their 
healthcare providers, it is equally critical for screening-eligible former smokers. Approximately 
60% of lung cancers are diagnosed in former smokers [1], making the shared decision-making 
process in this population critical in efforts of early detection and diagnosis of lung cancer for a 
population that may perceive they have a lower risk for lung cancer after having successfully 
quit smoking. More effort will be needed to raise the salience of lung cancer screening among 
former smokers through provider discussions. 
 In addition, the examination of prevalence trends pre- and post-lung cancer screening 
guidelines and sociodemographic characteristics from both years offers insight into the current 
state of patient-provider discussions about lung cancer screening. For example, the lack of 
racial/ethnic differences in conversations as well as prevalence that is similar to the U.S. 
population of blacks versus whites is encouraging as this may indicate a lack of disparity (i.e., 
equal numbers of discussions are occurring with black smokers compared to white smokers 
about lung cancer screening). However, this finding may be influenced by a floor effect due to 
the overall low prevalence of patient-provider discussions in both years across all racial/ethnic 
groups. Continued monitoring of the prevalence of patient-provider discussions about lung 
cancer screening among minorities will be important in the coming years to ensure there is no 
disparity in these discussions. 
 A few limitations should be acknowledged. The questions in HINTS did not differentiate 
whether the discussion about lung cancer screening was initiated by the patient or the provider. 
Future research should differentiate who is initiating the discussion in order to better target the 
group (i.e., patient and/or provider) that needs the most education. Further, while the single-item 
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measure of patient-provider discussion is adequate to examine the prevalence of these 
discussions, it does not encompass the complex dimensions of shared decision-making and 
should be viewed as a proxy. Additional research is needed to measure shared decision-making 
in the context of the lung cancer screening discussion to fully understand the process. In 
addition, because the HINTS did not report pack-year history for tobacco smoking, we were 
unable to perform analyses among participants who were eligible for lung cancer screening 
based on the pack-year criterion included in the USPSTF guidelines. Our analyses included 
individuals who self-identified as current or former smokers and our results may underestimate 
the true percentage of eligible smokers who have discussions with their healthcare providers 
about lung cancer screening. However, given that the vast majority of smokers initiate smoking 
prior to age 26 [14], and that we limited our sample to current smokers between the ages of 55 
and 80 years, it is plausible that the analyzed sample included long-term smokers rather than 
smokers who had initiated smoking recently.  
4.2 Conclusion 
 Lung cancer screening offers the opportunity to promote a patient-centered approach to 
cancer screening by involving patients through shared decision-making. The shared decision-
making process offers the healthcare provider the opportunity to address both the benefits and 
potential risks of lung cancer screening and work with their patients toward a mutually agreeable 
shared decision that acknowledges the individual’s preferences. To our knowledge, this is the 
first study to examine the prevalence of this critical component of the shared decision-making 
process in lung cancer screening and document a benchmark of prevalence in shared decision-
making in lung cancer screening using the patient-provider discussion as a proxy. Future 
research focused on shared decision-making in lung cancer screening must include an 
examination of all aspects of health communication, including potential perceived stigma in the 
clinical encounter, in order to enhance the shared decision-making process between healthcare 
providers and their high-risk patients. 
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4.3 Practice Implications 
Patient-provider discussions about lung cancer screening are low compared to 
discussions about other types of cancer screening. Increased awareness of the current inequity 
in these types of discussion can foster increased attention in the clinical encounter for high-risk 
current and former smokers.  This research highlights a critical need for healthcare 
providers to be educated, both formally and through training opportunities, on skills to 
encourage shared decision-making about lung cancer screening with eligible smokers. In 
addition, patient education about the shared decision-making process is also critical to 
fully engage patients in making informed decisions regarding their healthcare. Both 
provider and patient education about shared decision-making will not only improve 
patient-provider discussions about lung cancer screening, but may also benefit 
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Table 1 – Prevalence of discussion with healthcare providers about lung cancer screening 
and sample characteristics in 2012 and 2014 (weighted) 
 
 HINTS 4 Cycle 2, 2012 (n=746) HINTS 4 Cycle 4, 2014 (n=795) 
 
Weighted 
(% or M(SE)) 
Weighted 
(% or M(SE)) 
Talked to doctors or health professional   
No 75.1 85.5 
Yes 16.7 10.4 
Missing 8.1 4.1 
Age 65.1(0.3) 65.2(0.2) 
Gender   
Male 50.4 50.6 
Female 47.9 48.5 
Missing 1.7 0.9 
Race/ethnicity    
   White 73.7 68.8 
   Black 7.4 8.6 
   Hispanic 4.6 7.4 
   Other 2.0 3.1 
Missing 12.2 12.2 
Education    
Less than high school 17.6 17.7 
12 years or completed high school 22.6 21.5 
Post high school or some college 37.2 33.3 
College graduate or higher 22.1 26.0 
Missing 0.6 1.4 
Income     
Less than $20,000 23.8 21.6 
$20,000-35,000 15.8 15.9 
$35,000-50,000 14.2 16.2 
$50,000-75,000 16.9 16.8 
$75,000 or more 27.0 29.0 
Missing 2.2 0.5 
General health     
Excellent 7.0 5.2 
Very good 31.7 32.1 
Good 36.1 40.2 
Fair 18.2 16.7 
Poor 3.9 3.3 
Missing 3.1 2.6 
Smoking status    
Current smoker  29.0 27.7 
Former smoker 71.0 72.3 









Table 1. continued 
 HINTS 4 Cycle 2, 2012 (n=746) HINTS 4 Cycle 4, 2014 (n=795) 
 
Weighted 
(% or M(SE)) 
Weighted 
(% or M(SE)) 
 HINTS 4 Cycle 2, 2012 (n=746) HINTS 4 Cycle 4, 2014 (n=795) 
Family history of cancer    
No  31.5 25.5 
Yes 67.4 73.1 
Missing 1.1 1.4 
Health Insurance    
No 11.7 7.5 
Yes 86.9 90.4 
Missing 1.4 2.1 
 	
Table 2 – Logistic regression predicting talking to doctors or health professionals about 
lung cancer screening in 2012 and 2014 
 
 Adjusted OR 95% CI 
Survey year   
2012 (referent) 1  
2014  0.47*** [0.31,0.72] 
Age (years) 1.02 [0.99,1.06] 
Gender   
Male (referent) 1  
Female  0.80 [0.51,1.26] 
Race/ethnicity   
   White (referent) 1  
   Black 1.23 [0.71,2.13] 
   Hispanic 1.70 [0.74,3.91] 
   Other 1.32 [0.33,5.22] 
Education   
Less than high school (referent) 1  
12 years or completed high school 0.50 [0.22,1.11] 
Post high school or some college 0.84 [0.40,1.76] 
College graduate or higher 0.59 [0.25,1.39] 
Income    
Less than $20,000 (referent) 1  
$20,000-35,000 1.23 [0.56,2.69] 
$35,000-50,000 1.23 [0.56,2.71] 
$50,000-75,000 0.99 [0.45,2.21] 
$75,000 or more 1.19 [0.49,2.87] 
General health    
Excellent (referent) 1  
Very good 1.56 [0.47,5.15] 
Good 1.85 [0.59,5.82] 
Fair 1.51 [0.46,5.03] 
Poor 3.73 [0.79,17.64] 
Smoking status   
Former smoker (referent) 1  
Current smoker 2.25** [1.34,3.79] 
Personal history of cancer (except 
lung)   
No (referent) 1  
Yes 1.63 [0.92,2.87] 
Family history of cancer   
No (referent) 1  
Yes 2.53** [1.43,4.48] 
Health Insurance   
No (referent) 1  
Yes 2.90* [1.10,7.69] 
   
Note. *p<0.05; **p<0.01. Missing cases of talking to doctors (n=62 in 2012; n=34 in 2014). Missing values of 
predictor variables were treated as a separate category in the logistic regression models. Analyses were weighted to 
the U.S. general adult population using full sample and replicate weights provided in the HINTS data set. 
 
